WillItSurvive
Medical technology and health companies · United States

Caris Life Sciences

carislifesciences.com ↗

Runs molecular tumor profiling tests that guide cancer drug choices for oncologists.

Defensible for now
Assessed 22 July 2026 · Evidence as of 22 July 2026
Real protection, with named pressure against it.
On the recordSince 22 July 2026 · Checkable from August 5, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report
The call

Caris is growing fast and generating cash, but sits in a three-way race against Tempus AI and Foundation Medicine where pricing and share, not survival, decide the outcome.

Caris Life Sciences tests cancer tumors using DNA analysis to help doctors pick better treatments. The company is hard to replace because it has FDA-approved laboratories, contracts with 90+ insurance companies, and a database of 6.5 million test results that competitors would need years to build. However, Tempus AI and Foundation Medicine are much larger, better-funded rivals that are rapidly buying up smaller competitors (Tempus paid 1.5 billion dollars to acquire Personalis in mid-2026) and stealing market share. The biggest unknown: whether Caris can keep its share of the market and whether its new blood tests for early cancer detection (Caris Detect) will convince insurance companies to pay for them instead of rival products like Grail's Galleri test.

Why
01
AI pressure: Tempus AI. Tempus bundles AI-driven genomic interpretation with cheaper tests and just bought Personalis, pressuring Caris on price and share. Could AI do the core job? Unlikely.
02
Bigger players: Roche (via Foundation Medicine). Roche's balance sheet and existing oncology distribution let Foundation Medicine underprice and bundle against a smaller independent lab. Could a giant copy it? Probably.
03
What protects it. CLIA-certified labs, FDA clearances, over 90 payer contracts, and a 6.5 million-test outcomes database that a model alone can't replicate.
What would change this call
Caris case-volume growth trailing Tempus for two straight quarters. Would show Caris losing competitive share to Tempus.
Payer contracts resetting Caris's average selling price toward Tempus's lower level. Would show margin compression from competitive pricing pressure.
Caris Detect (MCED) payer coverage decisions relative to Grail's Galleri. Would show whether Caris's new product can gain adoption against an established rival.
Key numbers
  • Q1 2026 revenue $216M, up 79% YoY (2026-03-31)
  • FY2026 guidance $1.0-1.02B, ~23-26% growth (2026-02-26)
  • Caris ASP ~$4,300 vs Tempus ~$3,000 (2026-07-21)
Named risks
  • Tempus-Personalis consolidation (2026-07-20) could erode Caris's relative scale and payer leverage. Severity: high
  • Premium ASP (~$4,300 vs Tempus ~$3,000 per analyst estimate) exposes Caris to payer pricing pressure. Severity: medium
  • Caris Detect must win payer coverage against entrenched Grail Galleri in the MCED market. Severity: medium
  • Stock fell ~15.6% after-hours on 2026-05-14 despite beating estimates, signaling investor skittishness over revenue mechanics. Severity: medium
  • Headcount grew only ~2-5% YoY while revenue surged, raising questions about operational scaling limits. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Tempus AIcontestingTempus acquired Personalis for $1.5B on 2026-07-20, consolidating share as Caris grows 79% YoY in Q1 2026
Foundation Medicine (Roche)contestingLong-running patent dispute since 2017; both compete head-on in comprehensive genomic profiling
Guardant HealthcontestingViewed by analysts as liquid biopsy leader; Caris entering liquid biopsy via $45M Phoenix lab (2025)
Grail (Galleri)contestingCaris launched competing MCED test, Caris Detect, on 2026-07-01, entering Grail's screening market
Personalislosing toAcquired by Tempus for $1.5B on 2026-07-20, removing it as independent competitor but strengthening Tempus
Questions people ask
Is Caris Life Sciences profitable?
Caris turned cash-flow positive in FY2025, reporting free cash flow of $66.9M and operating cash flow of $83.2M for the year ended December 31, 2025, alongside revenue growth of about 97% YoY, per its February 26, 2026 earnings release.
Who owns Caris Life Sciences after its IPO?
Founder and CEO David Halbert retained about 43.7% ownership after the June 18, 2025 IPO, with Sixth Street holding roughly 9% and J.H. Whitney about 7.1%. As of July 20, 2026, insiders collectively held around 50% of shares, per MarketBeat.
How is Caris Life Sciences stock doing since its IPO?
Caris IPO'd at $21/share on June 18, 2025, closing day one at $28 (about $7.6-7.9B valuation). By May 14, 2026, shares fell ~15.6% after-hours despite beating Q1 2026 estimates ($216M revenue, up 79% YoY), on investor concerns over revenue true-up dynamics.
Who is Caris Life Sciences' biggest competitor?
Caris's closest rivals are Tempus AI, Foundation Medicine (Roche), and Guardant Health. Tempus announced a $1.5B acquisition of Personalis on July 20, 2026, consolidating the field just as Caris launched its own Caris Detect MCED test on July 1, 2026.
Could AI replace Caris Life Sciences' diagnostic business?
Unlikely to fully replace it: Caris's interpretation layer uses its DEAN AI engine, but its moat rests on CLIA-certified wet labs, FDA clearances (e.g., PTEN IHC), over 90 payer contracts, and a proprietary database of 6.5M+ tests, infrastructure a pure AI model cannot replicate.
What is Caris Detect and why does it matter?
Caris Detect is a multi-cancer early detection (MCED) blood test Caris commercially launched July 1, 2026, using ultra-deep whole genome and transcriptome sequencing plus AI, positioning it to compete directly with Grail's Galleri test in the screening market.
Timeline
  • 2026-07-21Caris reports over 90 payer contracts, one year post-IPO, per GenomeWeb
  • 2026-07-01Caris commercially launches Caris Detect, its MCED blood test
  • 2026-06-16Caris announces dual listing on NYSE Texas
  • 2026-06-08Board authorizes $100M share buyback program
  • 2026-05-14Q1 2026 revenue hits $216M (+79% YoY); stock drops ~15.6% after-hours
  • 2026-02-26Q4/FY2025 results: $292.9M Q4 revenue (+125% YoY); FY2026 guidance $1.0-1.02B
  • 2025-06-18Caris IPOs at $21/share, raising ~$494M, valued at $7.6-7.9B
  • 2024-01-01Caris Assure, blood-based molecular profiling test, broadly launched
  • 2017-01-01Caris files patent infringement suit against Foundation Medicine
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
AbridgeSeegeneOlympus Corporation
More in Medical technology and health companies →
Sources